收藏切换
Characteristics of comorbidities among reported hepatitis C cases in Nanchang and their association with antiviral treatment efficacy
收藏切换
Yong XIAO1, Jia-li MO2, Tian LUO2, Liang LU3, Zhi-bin TU3, Jie KUANG2
Modern Preventive Medicine | 2026, 53(5) : 947 - 953
Less
收藏切换
Modern Preventive Medicine | 2026, 53(5): 947-953
• Clinical Medicine and Prevention •
Characteristics of comorbidities among reported hepatitis C cases in Nanchang and their association with antiviral treatment efficacy
Full
Yong XIAO1, Jia-li MO2, Tian LUO2, Liang LU3, Zhi-bin TU3, Jie KUANG2
Affiliations
  • Nanchang Qingyunpu District Center for Disease Control and Prevention, Nanchang, Jiangxi 330001, China
Published: 2026-03-10 doi: 10.20043/j.cnki.MPM.202507370
Outline
收藏切换
Objective

To characterize the comorbidity profile of hepatitis C patients in Nanchang and evaluate its association with the efficacy of direct acting antivirals (DAAs) therapy.

Methods

We conducted a retrospective cohort study of 596 hepatitis C patients treated with DAAs in Nanchang between 2019 and 2024. Demographic data, comorbid conditions, and laboratory parameters were extracted from the hospital information system. The primary endpoint was sustained virological response 12 weeks post-treatment. Multivariable logistic regression models were used to examine the effect of comorbidities on treatment outcomes.

Results

A total of 596 patients were included, with a mean age of 55.1±13.6 years, and 60.9% were male (363/596).The overall prevalence of comorbidities was 34.2% (204/596). The four most common comorbidities were hypertension (18.8%,112/596), liver cirrhosis (13.6%, 81/596), diabetes (7.4%, 44/596), and hepatitis B virus (HBV) co-infection (3.5%, 21/596).Multivariable analysis showed that the presence of comorbidities was independently associated with DAA treatment failure (aOR=2.68, 95% CI: 1.31-5.49). In terms of specific comorbidities, concurrent hepatitis B virus infection (OR=4.80, 95% CI: 1.65-14.78) and diabetes mellitus (OR=2.43, 95% CI: 1.09-5.30) were identified as independent risk factors for antiviral treatment failure.

Conclusion

Hepatitis C patients in Nanchang bear a substantial comorbidity burden, which independently compromises DAA efficacy. We recommend a multidisciplinary care model integrating hepatology and endocrinology to strengthen integrated management of comorbidities and improve antiviral outcomes.

Hepatitis C  /  Comorbidity characteristics  /  Direct-acting antiviral therapy  /  Nanchang
肖勇, 莫佳丽, 罗田, 路亮, 涂志斌, 况杰. 南昌市既往报告丙型肝炎共病特征及与抗病毒治疗效果的相关性. 现代预防医学, 2026 , 53 (5) : 947 -953 . DOI: 10.20043/j.cnki.MPM.202507370
Yong XIAO, Jia-li MO, Tian LUO, Liang LU, Zhi-bin TU, Jie KUANG. Characteristics of comorbidities among reported hepatitis C cases in Nanchang and their association with antiviral treatment efficacy[J]. Modern Preventive Medicine, 2026 , 53 (5) : 947 -953 . DOI: 10.20043/j.cnki.MPM.202507370
Year 2026 volume 53 Issue 5
24
13
Cite this Article
BibTeX
Article Info
doi: 10.20043/j.cnki.MPM.202507370
  • Receive Date:2025-07-22
  • Online Date:2026-11-02
  • Published:2026-03-10
Article Data
Affiliations
History
  • Received:2025-07-22
Funding
Affiliations
    Nanchang Qingyunpu District Center for Disease Control and Prevention, Nanchang, Jiangxi 330001, China
References
Share
https://castjournals.cast.org.cn/joweb/xdyfyx/EN/10.20043/j.cnki.MPM.202507370
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT